Plasmacytoma
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
IL6,
MYC,
PVT1,
CD6,
BCL2,
CDKN2A,
CCND1,
MYOM2,
SMUG1,
SDC1,
H3P10,
BCL10,
IGF1,
IL2,
VEGFA,
IL6R,
RTEL1,
TP53,
SOAT1,
PTPRC,
PAX5,
FANCD2,
PCNA,
CD19,
CD79A,
BCL2L1,
AICDA,
LOC102723407,
LOC390714,
XBP1
IL6,
MYC,
PVT1,
CD6,
BCL2,
CDKN2A,
CCND1,
MYOM2,
SMUG1,
SDC1,
H3P10,
BCL10,
IGF1,
IL2,
VEGFA,
IL6R,
RTEL1,
TP53,
SOAT1,
PTPRC,
PAX5,
FANCD2,
PCNA,
CD19,
CD79A,
BCL2L1,
AICDA,
LOC102723407,
LOC390714,
XBP1,
MIR208A,
CD24,
MIR1206,
TNF,
TRBV20OR9-2,
STAT3,
STAT1,
SHBG,
NR0B2,
LOC102724971,
LOC105379528,
PTPN6,
PTEN,
PSMB5,
MAPK3,
POU2AF1,
PIGA,
ERVK-32,
H3P9,
ABCB4,
MZF1,
SOCS1,
PBK,
SOCS2,
CCHCR1,
KRT20,
TLR9,
ERVK-6,
NXT1,
IGHV3-69-1,
RTL10,
IGHV3OR16-7,
SGSM3,
FOXP1,
SETBP1,
DBA2,
SUB1,
MRPL28,
PECAM1,
TNFSF15,
NUAK1,
NAPSA,
ATG5,
INA,
SELENBP1,
IL23R,
BHLHA15,
EBI3,
ABL1,
PCYT1A,
CSNK1A1,
FKBP1AP4,
FKBP1AP3,
FKBP1AP2,
FKBP1AP1,
FKBP1A,
FGFR3,
EPOR,
EPO,
EEF1A2,
EBF1,
DPP4,
DAPK1,
DAP,
CSF3,
FOXM1,
CDKN2B,
CDK4,
CD38,
TNFRSF8,
MS4A1,
CAT,
CAD,
BTK,
BRAF,
CXCR5,
PRDM1,
ATM,
ALK,
FKBP2,
FLNC,
PCM1,
IRF4,
MTTP,
MMP13,
AKT1,
MLH1,
CD99,
MGMT,
MCL1,
MBD1,
LPL,
LAIR1,
KIT,
ITGB2,
ITGAL,
IL12RB2,
FN1,
IL10,
IL6ST,
IL3,
IL1B,
IL1A,
IGHM,
IGH,
IFNA13,
IFNA1,
ICAM1,
GNA15,
GLS,
GATA1,
MMP8
Drugs
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
Plasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms. There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues. Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations.